Highlights and Quick Summary
- Annual Cash ROIC for 2020 was -13.72% (a 79.11% increase from previous year)
- Annual Cash ROIC for 2019 was -7.66% (a -88.45% decrease from previous year)
- Twelve month Cash ROIC ending June 29, 2021 was -32.41% (a 35.72% increase compared to previous quarter)
- Twelve month trailing Cash ROIC increased by 115.49% year-over-year
Trailing Cash ROIC for the last four month:
| 29 Jun '21 | 30 Mar '21 | 30 Dec '20 | 29 Sep '20 |
|---|---|---|---|
| -32.41% | -23.88% | -13.09% | -15.04% |
Visit stockrow.com/PHAT
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Cash ROIC of Phathom Pharmaceuticals, Inc.
Most recent Cash ROICof PHAT including historical data for past 10 years.Interactive Chart of Cash ROIC of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Cash ROIC for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2020 | – | – | – | – | -13.72% |
| 2019 | – | – | – | – | -7.66% |
| 2018 | – | – | – | – | -66.3% |
Business Profile of Phathom Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.